Endocrine disorders (parathyroid hormone).
In summary, precise PTH measurements have been difficult and complex as a result of low circulating concentrations of biologically active hormone and the immunoheterogeneity of circulating PTH molecules. The differences in secretion rates and metabolism of various PTH fragments in different clinical disorders further complicated the interpretation of various radioimmunoassable PTH levels. In recent years, the development of two-site or intact immunometric assays represents significant advancements in PTH measurement. These assays, for the first time, provide the long-awaited sensitivity and precision of PTH measurement. The IRMA assay has certainly overcome the difficulties in accurately diagnosing parathyroid disorders and the difficulties in the differential diagnosis of hypercalcemia. Above all, these assays are more convenient and more specific in patients with compromised renal function.